Indian generic drugmakers such as Sun Pharma, Cipla, Dr Reddy's and Lupin are beginning to develop their own versions of Novo Nordisk's blockbuster weight-loss drug Wegovy. Some analysts predict the weight-loss drug market could reach $100 billion annually by 2030 as obesity rates rise globally. Novo Nordisk has been unable...
Novartis’ Cardiac Drug to Go Off-Patent in January
Swiss-American multinational pharmaceutical, Novartis AG's drug Vymada or Entresto used for patients with heart failure becomes off-patent in January, 2023 Heart failure is a progressive chronic syndrome characterized by a decrease in the functions of the heart and quality of life. 23 million people are affected by it worldwide, while...
Medis, Axantis, Source Orphan Drugs from India’s Lupin
Mumbai-based global pharma major Lupin, signed a distribution agreement with Slovenia-based Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in...
Medis, Axantia, Source Orphan Drugs from India’s Lupin
Mumbai-based global pharma major Lupin, signed a distribution agreement with Slovenia-based Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in...
Lupin of India launches device
India's Lupin Limited announced the launch of “ADHERO,” a new connected smart device for metered-dose inhalers (MDI) . This first-of-its-kind device is designed to help patients with chronic respiratory diseases track their inhaler usage and facilitate improved adherence to therapy. Inhalers are the preferred treatment option for managing the rising...
51 Indian Pharma Companies Get ANDA Approvals
Fifty-one of the 112 approvals for abbreviated new drug applications (ANDA) given by the USFDA went to India. Further, Indian companies received 6 tentative approvals from an aggregate of 23 tentative approvals in the Jan-March quarter of 2018. With eleven ANDA approvals, Aurobindo Pharma received the highest number among the...